融合MRI引导与认知引导前列腺穿刺在初诊患者中的头对头随机对照试验
该头对头随机对照试验纳入PSA 2–10 ng/dL的初诊前列腺穿刺患者,比较融合MRI引导靶向穿刺(fus-MRGB)联合系统穿刺(SB)与认知引导靶向穿刺(cog-MRGB)联合SB的诊断效能。结果显示fus-MRGB组总体及临床显著前列腺癌检出率均显著高于cog-MRGB组,推荐优先使用fus-MRGB。
要点
- fus-MRGB联合SB的总体前列腺癌检出率44.4%,显著高于cog-MRGB联合SB的31.0%(p=0.035)。
- fus-MRGB联合SB的临床显著前列腺癌检出率33.3%,显著高于cog-MRGB联合SB的19.0%(p=0.016)。
- 在PSA 2–10 ng/dL的初诊患者中,若条件允许应优先选择fus-MRGB而非cog-MRGB。
核心结论
- 在PSA 2–10 ng/dL的初诊前列腺穿刺患者中,fus-MRGB联合SB检测总体及临床显著前列腺癌的准确性显著高于cog-MRGB联合SB。
研究设计与样本
- 头对头随机对照试验,纳入PSA 2–10 ng/dL的初诊前列腺穿刺候选患者,所有患者行多参数MRI,PI-RADS评分≥3的可疑病灶患者随机分组。
主要发现
- fus-MRGB组总体前列腺癌检出率为44.4%,cog-MRGB组为31.0%,差异显著(p=0.035)。
- fus-MRGB组临床显著前列腺癌检出率为33.3%,cog-MRGB组为19.0%,差异显著(p=0.016)。
临床怎么用
- 对于PSA 2–10 ng/dL的初诊前列腺穿刺患者,若融合MRI引导穿刺可用,推荐优先选择fus-MRGB联合SB而非cog-MRGB联合SB。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The combination of MRI-guided targeted biopsy (MRGB) with systematic biopsy (SB) provides the highest accuracy in detecting prostate cancer. There is a controversy over the superiority of fusion targeted biopsy (fus-MRGB) over cognitive targeted biopsy (cog-MRGB). The present head-to-head randomized controlled trial was performed to compare diagnostic yield of fus-MRGB in combination with SB with cog-MRGB in combination with SB. METHODS: Biopsy-naive patients with a prostate-specific antigen level between 2 and 10 ng/dL who were candidates for prostate biopsy were included in the study. Multiparametric MRI was performed on all patients and patients with suspicious lesions with Prostate Imaging Reporting and Data System score of 3 or more were randomized into two groups. In the cog-MRGB group, a targeted cognitive biopsy was performed followed by a 12-core SB. Similarly, in the fus-MRGB group, first targeted fusion biopsy and then SBs were performed. The overall and clinically significant prostate cancer detection rates between the two study groups were compared by the Pearson χ2 test. McNemar test was used to compare detection rates yielded by SB and targeted biopsy in each study group. RESULTS: One-hundred men in the cog-MRGB group and 99 men in the fus-MRGB group were compared. The baseline characteristics of patients including age, PSA level, prostate volume, PSA density, and clinical stage were similar in the two groups (p > 0.05). Both the overall and clinically significant prostate cancer detection rates in the fus-MRGB group (44.4% and 33.3%, respectively) were significantly higher than cog-MRGB group (31.0% and 19.0%, respectively) (p = 0.035 and p = 0.016, respectively). CONCLUSION: The accuracy of identifying overall and clinically significant prostate cancer by fus-MRGB in biopsy-naive patients with PSA levels between 2 and 10 ng/dL is significantly higher than cog-MRGB and if available, we recommend using fus-MRGB over cog-MRGB in these patients.
引用
- Izadpanahi MH, Elahian A, Gholipour F, et al. Diagnostic yield of fusion magnetic resonance-guided prostate biopsy versus cognitive-guided biopsy in biopsy-naive patients: a head-to-head randomized controlled trial. Prostate Cancer Prostatic Dis. 2021. PMID: 33907293. doi:10.1038/s41391-021-00366-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。